Myocardial infarct: no one size fits all.
Pfeffer
Marc A
MA
McMurray
John J V
JJ
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D002121:Calcium Channel Blockers / Q000009:adverse effects; D002986:Clinical Trials as Topic / Q000639:trends; D003325:Coronary Care Units; D004059:Diffusion of Innovation; D019468:Disease Management; D004359:Drug Therapy, Combination; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006321:Heart / Q000503:physiopathology; D006801:Humans; D000451:Mineralocorticoid Receptor Antagonists / Q000627:therapeutic use; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000401:mortality / Q000503:physiopathology; D018570:Risk Assessment; D013997:Time Factors; D016896:Treatment Outcome
D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000894:Anti-Inflammatory Agents, Non-Steroidal; D002121:Calcium Channel Blockers; D005343:Fibrinolytic Agents; D000451:Mineralocorticoid Receptor Antagonists